Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma

Angiosarcoma is an aggressive malignancy of vascular origin that occurs de novo or in the context of previous cancer therapy. Despite multi-modal aggressive treatment including surgical resection, chemotherapy, and radiation, five-year overall survival remains poor at 35%. Due to its rarity, little...

Descripción completa

Detalles Bibliográficos
Autores principales: Chadwick, Michelle L., Lane, Adam, Thomas, Dana, Smith, Amanda R., White, Angela R., Davidson, Dominique, Feng, Yuxin, Boscolo, Elisa, Zheng, Yi, Adams, Denise M., Gupta, Anita, Veillette, André, Chow, Lionel M.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973867/
https://www.ncbi.nlm.nih.gov/pubmed/29872503
http://dx.doi.org/10.18632/oncotarget.25345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973867/
https://www.ncbi.nlm.nih.gov/pubmed/29872503
http://dx.doi.org/10.18632/oncotarget.25345

Ejemplares similares